Business Context and Reporting Period
This Form 6-K filing by Frontline Plc covers the month of September 2025. The report serves to disclose specific corporate actions regarding the company's synthetic option scheme, including new grants to management and employees and the exercise of options by directors and executives. The filing does not contain a financial results report for the period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions. Key metrics related to these transactions include:
- New Grant Exercise Price: USD 16.80 (volume-weighted average price over the last 30 days prior to the May 27, 2025 grant).
- Dividend Adjustments: Exercise prices for older options were adjusted downward due to dividends paid since grant (e.g., $5.35 and $5.71 per share adjustments noted).
- Transaction Volumes: 362,284 options granted; 154,000 options exercised in September 2025.
Material Changes
There are no material changes to financial performance reported in this filing. The material events disclosed are:
- Grant of Synthetic Options: On May 27, 2025, the Company granted 362,284 synthetic options to management and employees. These options have a five-year term expiring May 27, 2030, and vest in three equal tranches annually from 2026 to 2028.
- Executive Exercises:
- On September 8, 2025, Director James O'Shaughnessy exercised 44,000 synthetic options.
- On September 12, 2025, CEO Lars H. Barstad exercised 110,000 synthetic options. Following this transaction, Mr. Barstad holds 405,509 synthetic options.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the standard terms of the option scheme. Notable terms include:
- Settlement: Options are settled in cash based on the difference between the market price and the exercise price.
- Gain Caps: Options granted to the CEO and CFO are subject to a cap on maximum annual gain equal to two times the annual base salary at the time of exercise.
- Dividend Adjustments: Exercise prices are adjusted for any dividends distributed before exercise.
Investor Verification Checklist
- Verify the current market price of Frontline Plc shares to assess the intrinsic value of the recently exercised options.
- Confirm the total number of outstanding synthetic options and the dilution impact (if any) on the cash settlement obligations.
- Review the Company's dividend policy and recent payout history to understand the frequency of exercise price adjustments.
- Check the vesting schedule for the 362,284 new options to understand future cash settlement liabilities.